Trials / Active Not Recruiting
Active Not RecruitingNCT02984566
Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)
LARK: Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- University of Sydney · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Primary and secondary liver cancer patients will receive liver SABR with or without KIM intervention.
Detailed description
This is a single arm, phase II, two stage study designed to evaluate cancer targeting accuracy, treatment outcomes and treatment efficiency in 46 patients eligible for SABR for either primary or secondary liver malignancy with the incorporation of KIM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Kilovoltage Intrafraction Monitoring | KIM is a novel intrafraction real-time tumour localization method. It involves a single gantry-mounted kV x-ray imager acquiring 2D projections of implanted fiducial markers. 3D positions are then reconstructed by maximum likelihood estimation of a 3D probability density function. |
Timeline
- Start date
- 2020-01-14
- Primary completion
- 2026-01-01
- Completion
- 2026-01-01
- First posted
- 2016-12-07
- Last updated
- 2025-04-04
Locations
4 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT02984566. Inclusion in this directory is not an endorsement.